PL1718338T3 - Kompozycje oraz sposoby do celowanego dostarczania leku in vitro oraz in vivo do ssaczych komórek poprzez bakteriopochodne nienaruszone minikomórki - Google Patents

Kompozycje oraz sposoby do celowanego dostarczania leku in vitro oraz in vivo do ssaczych komórek poprzez bakteriopochodne nienaruszone minikomórki

Info

Publication number
PL1718338T3
PL1718338T3 PL05702361T PL05702361T PL1718338T3 PL 1718338 T3 PL1718338 T3 PL 1718338T3 PL 05702361 T PL05702361 T PL 05702361T PL 05702361 T PL05702361 T PL 05702361T PL 1718338 T3 PL1718338 T3 PL 1718338T3
Authority
PL
Poland
Prior art keywords
vitro
targeted
compositions
methods
drug delivery
Prior art date
Application number
PL05702361T
Other languages
English (en)
Inventor
Himanshu Brahmbhatt
Jennifer Macdiarmid
Original Assignee
Engeneic Molecular Delivery Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Engeneic Molecular Delivery Pty Ltd filed Critical Engeneic Molecular Delivery Pty Ltd
Publication of PL1718338T3 publication Critical patent/PL1718338T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
PL05702361T 2004-02-02 2005-01-27 Kompozycje oraz sposoby do celowanego dostarczania leku in vitro oraz in vivo do ssaczych komórek poprzez bakteriopochodne nienaruszone minikomórki PL1718338T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54059004P 2004-02-02 2004-02-02
EP20050702361 EP1718338B1 (en) 2004-02-02 2005-01-27 Compositions and methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells
PCT/IB2005/000204 WO2005079854A1 (en) 2004-02-02 2005-01-27 Compositions and methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells

Publications (1)

Publication Number Publication Date
PL1718338T3 true PL1718338T3 (pl) 2015-12-31

Family

ID=34885947

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05702361T PL1718338T3 (pl) 2004-02-02 2005-01-27 Kompozycje oraz sposoby do celowanego dostarczania leku in vitro oraz in vivo do ssaczych komórek poprzez bakteriopochodne nienaruszone minikomórki

Country Status (19)

Country Link
US (3) US9867785B2 (pl)
EP (2) EP1718338B1 (pl)
JP (2) JP5060787B2 (pl)
CN (2) CN102028953B (pl)
AU (2) AU2005215254B2 (pl)
CA (2) CA2556248C (pl)
DK (2) DK2992901T3 (pl)
ES (2) ES2765426T3 (pl)
HK (1) HK1155665A1 (pl)
HR (1) HRP20150828T8 (pl)
HU (1) HUE025292T2 (pl)
ME (1) ME02251B (pl)
NZ (1) NZ549139A (pl)
PL (1) PL1718338T3 (pl)
PT (1) PT1718338E (pl)
RS (1) RS54149B1 (pl)
SG (3) SG135175A1 (pl)
SI (1) SI1718338T1 (pl)
WO (1) WO2005079854A1 (pl)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8986736B2 (en) 2003-06-24 2015-03-24 Baxter International Inc. Method for delivering particulate drugs to tissues
EP1663158A2 (en) 2003-06-24 2006-06-07 Baxter International Inc. Specific delivery of drugs to the brain
PT1718338E (pt) * 2004-02-02 2015-09-21 Engeneic Molecular Delivery Pty Ltd Composições e métodos de libertação direcionada de fármacos in vitro e in vivo por meio de minicélulas intactas derivadas de bactérias
CA2565972A1 (en) 2004-06-15 2005-12-29 Baxter International Inc. Ex-vivo application of solid microparticulate therapeutic agents
MX2007002294A (es) 2004-08-26 2007-10-19 Engeneic Molecular Delivery Pty Ltd Suministro de acidos nucleicos funcionales a celulas mamiferas via minicelulas intactas, derivadas bacterialmente.
DK2865755T3 (en) 2007-03-30 2017-05-15 Engeneic Molecular Delivery Pty Ltd BACTERIAL DERIVATIVE INTACT MINICELLS WITH REGULATORY RNA
CA2697629A1 (en) 2007-09-24 2009-04-02 The University Of Queensland Molecular delivery vesicle
AU2009206748B2 (en) * 2008-01-22 2014-03-20 Araim Pharmaceuticals, Inc. Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
WO2009111638A1 (en) 2008-03-05 2009-09-11 Baxter International Inc. Compositions and methods for drug delivery
KR101623999B1 (ko) 2008-06-25 2016-05-24 벡션 테라퓨틱스 엘엘씨 조절된 유전자 자살 메커니즘 조성물 및 방법
US10952965B2 (en) 2009-05-15 2021-03-23 Baxter International Inc. Compositions and methods for drug delivery
JP5667180B2 (ja) 2009-07-01 2015-02-12 イオン メディックス インコーポレイテッド 哺乳類の有核細胞に由来するマイクロベシクル及びその用途
IT1401457B1 (it) * 2010-06-11 2013-07-26 Fond I R C C S Istituto Neurologico Carlo Besta Carrier di tipo cellulare per il trasporto mirato di almeno una molecola e/o almeno un composto molecolare ad almeno una cellula bersaglio in un mammifero umano o non umano
CN103002879B (zh) 2010-07-01 2016-04-20 阿昂梅迪克斯公司 来自细胞原生质体的微泡及其应用
JP6199746B2 (ja) 2011-02-15 2017-09-20 バキシオン セラピューティクス，リミテッド ライアビリティ カンパニー 抗体およびＦｃ含有標的化分子に基づく生理活性分子の標的送達のための細菌ミニ細胞による治療用組成物および方法
MX359410B (es) * 2011-12-13 2018-09-27 Engeneic Molecular Delivery Pty Ltd Minicélulas intactas derivadas bacterialmente para suministro de agentes terapéuticos a tumores cerebrales.
AU2013327059B2 (en) 2012-10-02 2018-11-08 Vaxiion Therapeutics, Llc Immunomodulatory minicells and methods of use
US9733222B2 (en) * 2012-10-03 2017-08-15 Waters Technologies Corporation Rapid analysis of steroids and steroid derivatives
US20160120818A1 (en) * 2013-02-07 2016-05-05 Glaxosmithline Biological Sa Pharmaceutical compositions comprising vesicles
US10314916B2 (en) 2013-06-11 2019-06-11 House Wellness Foods Corporation Carrier for delivery of substance to phagocytes
CA2926161C (en) 2013-10-04 2023-03-14 Engeneic Molecular Delivery Pty Ltd Combination tumor treatment with drug-loaded, bispecific ligand-targeted minicells and interferon-gamma
JP7029957B2 (ja) * 2014-10-03 2022-03-04 エンジーンアイシー モレキュラー デリバリー ピーティーワイ リミテッド インタクトな細菌由来のベシクルへの低分子化合物の充填の向上
CN104388459B (zh) * 2014-10-29 2017-03-08 四川农业大学 使细菌自主产微细胞的方法及一株自产微细胞细菌突变株
KR101708424B1 (ko) * 2015-03-04 2017-02-20 전남대학교산학협력단 코리네박테리움 속 박테리아 및 이로부터 유래된 미니셀 그리고 이의 용도
KR101858840B1 (ko) * 2016-01-15 2018-05-16 단국대학교 천안캠퍼스 산학협력단 집먼지진드기 유래 알레르겐에 의한 과민반응 면역조절제
WO2017192863A1 (en) 2016-05-04 2017-11-09 L.E.A.F. Holdings Group Llc Targeted liposomal gemcitabine compositions and methods thereof
CN110022905B (zh) 2016-10-06 2024-02-06 安吉尼科分子传输公司 用于递送核酸佐剂的细菌小细胞和使用其的方法
EP3649242A2 (en) 2017-07-06 2020-05-13 National University of Singapore Methods of inhibiting cell proliferation and mettl8 activity
WO2019204154A1 (en) 2018-04-18 2019-10-24 Reyoung Corporation Compositions and methods for treating liver cancer
WO2019217164A1 (en) 2018-05-09 2019-11-14 Reyoung Corporation Compositions and methods for treating cancer and other diseases
CN112689511A (zh) 2018-07-23 2021-04-20 安吉尼科分子传输公司 包含细菌源微细胞的组合物及其使用方法
EP3952645A4 (en) * 2019-04-08 2023-08-23 University Of Massachusetts LOCALIZATION OF PAYLOAD DELIVERY SYSTEMS TO TUMOR SITES USING BEACON CELL TARGETING
WO2020222161A1 (en) * 2019-05-01 2020-11-05 Engeneic Molecular Delivery Pty Ltd Compositions comprising bacterially derived intact minicells for theranostic applications
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
CN114053430A (zh) * 2020-07-29 2022-02-18 深圳先进技术研究院 一种负载纳米载药颗粒的细菌及其制备方法和应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4496778A (en) 1983-10-03 1985-01-29 Exxon Research & Engineering Co. Process for the hydroxylation of olefins using molecular oxygen, an osmium containing catalyst, a copper Co-catalyst, and an aromatic amine based promoter
CA1270198A (en) 1984-08-08 1990-06-12 Marcel B. Bally Encapsulation of antineoplastic agents in liposomes
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
IL91664A (en) 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5549910A (en) * 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
WO1995021191A1 (en) 1994-02-04 1995-08-10 William Ward Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
US5800833A (en) 1995-02-27 1998-09-01 University Of British Columbia Method for loading lipid vesicles
AU5557796A (en) 1995-04-18 1996-11-07 Dehlinger, Peter J. Liposome drug-loading method and composition
US5837282A (en) 1996-10-30 1998-11-17 University Of British Columbia Ionophore-mediated liposome loading
IL145778A0 (en) 1999-04-21 2002-07-25 American Home Prod Methods and compositions for inhibiting the function of polynucleotide sequences
US6635448B2 (en) 2000-08-21 2003-10-21 Clonexdevelopment, Inc. Methods and compositions for increasing protein yield from a cell culture
IL157794A0 (en) 2001-03-07 2004-03-28 Childrens Medical Center Method to screen peptide display libraries using minicell display
US7011946B2 (en) 2001-05-22 2006-03-14 Trustees Of Tufts College In vivo assay for identification of antimicrobial agents
US20030194798A1 (en) * 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
US20030166099A1 (en) * 2001-06-05 2003-09-04 Sabbadini Roger A. Minicells comprising membrane proteins
JP4458846B2 (ja) * 2001-10-15 2010-04-28 エンジーンアイシー モレキュラー デリバリー ピーティーワイ リミテッド ｉｎｖｉｔｒｏおよびｉｎｖｉｖｏにおけるＤＮＡ導入および遺伝子療法のためのベクターとしての完全なミニ細胞
EP2272946B9 (en) * 2002-02-25 2015-06-24 Vaxiion Therapeutics, LLC Minicell compositions and methods
US20030203481A1 (en) * 2002-02-25 2003-10-30 Surber Mark W. Conjugated minicells
US20030207833A1 (en) 2002-02-25 2003-11-06 Neil Berkley Pharmaceutical compositions with minicells
US7611885B2 (en) 2003-06-24 2009-11-03 Engeneic Molecular Delivery Pty, Ltd. Pharmaceutically compatible method for purifying intact bacterial minicells
PL1694361T3 (pl) 2003-12-09 2011-08-31 Engeneic Molecular Delivery Pty Ltd Ukierunkowane dostarczanie genów do niefagocytujących komórek ssaczych z zastosowaniem nienaruszonych minikomórek pochodzących od bakterii
PT1718338E (pt) * 2004-02-02 2015-09-21 Engeneic Molecular Delivery Pty Ltd Composições e métodos de libertação direcionada de fármacos in vitro e in vivo por meio de minicélulas intactas derivadas de bactérias
MX2007002294A (es) 2004-08-26 2007-10-19 Engeneic Molecular Delivery Pty Ltd Suministro de acidos nucleicos funcionales a celulas mamiferas via minicelulas intactas, derivadas bacterialmente.
EP1838838B1 (en) 2004-12-17 2010-09-01 Beth Israel Deaconess Medical Center Compositions for bacterial mediated gene silencing and methods of using same
EP2040725B1 (en) 2006-06-23 2014-01-15 EnGeneIC Molecular Delivery Pty Ltd. Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells via intact killed bacterial cells

Also Published As

Publication number Publication date
EP2992901A1 (en) 2016-03-09
DK2992901T3 (da) 2020-01-27
EP1718338B1 (en) 2015-05-06
JP5060787B2 (ja) 2012-10-31
EP1718338A1 (en) 2006-11-08
US20140220116A1 (en) 2014-08-07
US10799461B2 (en) 2020-10-13
CN102028953A (zh) 2011-04-27
CN102028953B (zh) 2013-10-30
HRP20150828T1 (en) 2015-09-11
CA2556248C (en) 2013-04-02
US20180133163A1 (en) 2018-05-17
EP2992901B1 (en) 2019-10-23
CA2788707C (en) 2014-02-25
US20180280311A1 (en) 2018-10-04
CN1925873B (zh) 2011-02-09
ME02251B (me) 2015-12-31
AU2005215254A1 (en) 2005-09-01
JP5571031B2 (ja) 2014-08-13
JP2007534667A (ja) 2007-11-29
NZ549139A (en) 2009-11-27
SG169373A1 (en) 2011-03-30
AU2005215254B2 (en) 2009-11-12
HUE025292T2 (en) 2016-02-29
PT1718338E (pt) 2015-09-21
HK1155665A1 (en) 2012-05-25
AU2010200599A1 (en) 2010-03-11
SI1718338T1 (sl) 2015-09-30
ES2765426T3 (es) 2020-06-09
SG135174A1 (en) 2007-09-28
CA2788707A1 (en) 2005-09-01
EP1718338A4 (en) 2009-07-22
AU2010200599B2 (en) 2011-09-22
SG135175A1 (en) 2007-09-28
US9867785B2 (en) 2018-01-16
JP2011178798A (ja) 2011-09-15
CN1925873A (zh) 2007-03-07
DK1718338T3 (en) 2015-08-10
HRP20150828T8 (hr) 2016-04-22
WO2005079854A1 (en) 2005-09-01
ES2544652T3 (es) 2015-09-02
RS54149B1 (en) 2015-12-31
CA2556248A1 (en) 2005-09-01

Similar Documents

Publication Publication Date Title
HRP20150828T8 (hr) Kompozicije i postupci in vitro i in vivo ciljanog oslobađanja lijeka u stanicama sisavaca, preko intaktnih mini-stanica izvedenih iz bakterija
EP2195001A4 (en) METHOD FOR THE PRODUCTION AND USE OF A CELL-PENETRATING PEPTIDE FOR IMPROVED DELIVERY OF NUCLEIC ACIDS, PROTEINS, MEDICAMENTS AND ADENOVIRES ON TISSUES AND CELLS AND COMPOSITIONS AND KITS
EP1594883A4 (en) COVALENT MODIFICATION OF RNA FOR DISTRIBUTION IN VITRO / I AND IN VIVO / I
EP1791959A4 (en) DISPOSAL OF FUNCTIONAL NUCLEIC ACIDS ON MAMMALIAN CELLS OVER BACTERIA ORIGINAL INTACT MINIMIZERS
HK1136848A1 (en) Compositions for enhancing delivery of double-stranded rna to regulate gene expression in mammalian cells rna
IL266122A (en) Stable serum-free cell-to-cell gene transfer and production of recombinant human proteins in human cell lines
IL243462A (en) Oligomers and phosphate-based conjugates for insertion of drugs into living cells and cell nuclei
PL2089511T3 (pl) Rozrost in vitro komórek pochodzących z tkanki pępowinowej wykorzystujących mikronośniki
EP1636385A4 (en) INHIBITION OF GENE FUNCTION BY IN VIVO DISTRIBUTION OF GENE EXPRESSION INHIBITORS BASED ON POLYNUCLEOTIDES IN MAMMALIAN CELLS
IL180077A (en) In vitro Methods, Their Use, and Preparations to Encourage Oligodendrocyte Differentiation or Survival Using Lingo-1 Antagonist Antibodies
EP2049130A4 (en) SOFT TISSUE LOAD COMPOSITION COMPRISING AUTOLOGOUS CELL CULTURE PRODUCT DERIVED FROM DERMA AND HYALURONIC ACID
HK1079987A1 (zh) 使用細胞脫唾液酸決定簇和糖綴合物將細胞靶向組織和器官的方法和組合物
WO2007147014A3 (en) Method and systems for using biopolymer-based beads and hydrogels
EP2155235A4 (en) OXYGEN GENERATING COMPOSITIONS FOR INCREASING THE SURVIVAL OF IN VIVO CELLS AND TISSUES
IL186535A0 (en) Pharmaceutical compositions for elimination of heterogeneous and mixed cell populations in tumors
WO2011082038A3 (en) Improved reprogramming compositions
WO2010062911A3 (en) Compositions and methods of functionally enhanced in vitro cell culture system
EP1791952A4 (en) COMPOSITIONS AND METHODS OF SELF-RENEWAL AND DIFFERENTIATION IN HUMAN EMBRYONAL STEM CELLS
EP1971355A4 (en) METHOD AND COMPOSITIONS FOR THE DISPOSAL OF ACTIVE SUBSTANCES WITH IMPROVED PHARMACOLOGICAL PROPERTIES
IL173965A (en) Peptide compounds, pharmaceutical preparations containing them, uses and methods in vitro and ex vivo to activate a thrombopoietin receptor in the cell
WO2008147816A3 (en) Compositions and methods for the display of proteins on the surface of bacteria and their derived vesicles and uses thereof
EP1804832A4 (en) METHOD AND COMPOSITIONS FOR THE NADLESS DELIVERY OF MACROMOLECULES
WO2006045116A3 (en) In vivo site-specific incorporation of n-acetyl-galactosamine amino acids in eubacteria
EP1589999A4 (en) POLYVINYL ETHER FOR THE ADMINISTRATION OF POLYNUCLEOTIDES IN MAMMALIAN CELLS
EP1980274A4 (en) CORNEAL ENDOTHELIAL PREPARATION THAT ALLOWS CELLS TO GROW IN VIVO